ClinicalTrials.gg
Not yet recruitingNCT07297550Updated Dec 22, 2025

Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia

A Phase 1/2 interventional study of Golidocitinib Capsules in Severe Aplastic Anemia, Refractory Aplastic Anemia and Newly Diagnosed Aplastic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
12th of 25
42 · median 40
Started
2025
with 7 others
Phase 1/2
3 of 31
3 open now
Primary completion
2026-12
later than 4 of 17 live
Registered
26th of 31
by date

Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 8 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 4 of the 17 other live ones, and was the 26th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This study is designed as a Phase Ib/II trial. The phase Ib cohort will enroll patients with severe aplastic anemia (SAA) who have failed to respond to intensified immunosuppressive therapy. In contrast, the phase II cohort will include newly diagnosed and treatment-naïve patients with SAA. A Safety Review Committee (SRC), chaired by the principal investigators, will be established to oversee patient safety throughout the study. Suppose the Phase Ib results demonstrate acceptable safety and tolerability. In that case, the data will be submitted to the Ethics Committee for review, and, upon approval, the study will advance to Phase II.

Phase Ib uses a 3+3 dose-escalation design with two cohorts: 150 mg golidocitinib orally every other day (low dose) or once daily (high dose). Phase II is a single-arm trial with Simon's two-stage optimal design.

03

Conditions studied

  • Severe Aplastic Anemia
  • Refractory Aplastic Anemia
  • Newly Diagnosed Aplastic Anemia

Browse trials for

Keywords

  • JAK1 inhibitor
  • Intensive immunosuppressive therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Phase Ib:

Inclusion Criteria:

  • According to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition) and the Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (Br J Haematol. 2024; 204: 784-804), the patient is diagnosed with primary acquired AA and meets the diagnostic criteria for SAA.
  • Subjects received intensive therapy combined with a standard-dose TPO receptor agonist for at least 4 months but failed to respond or experienced relapse.
  • Unsuitable for or unwilling to undergo hematopoietic stem cell transplantation and lacking other superior treatment options.
  • Age ≥ 18 years
  • performance status ≤2
  • Willing and able to comply with the requirements for this study and written .

Exclusion Criteria:

  • Presence of any other primary or secondary bone marrow failure syndrome, including but not limited to Fanconi anemia, myelodysplastic syndrome (MDS), clonal cytopenia of undetermined significance, or large granular lymphocytic leukemia.
  • Bone marrow reticulin fibrosis ≥ grade 2
  • Subjects with a paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50% or with evidence of active hemolysis.
  • Presence of clonal cytogenetic abnormalities characteristic of MDS, excluding +8, del(20q), and -Y.
  • Active infection within 2 weeks before first dosing of the product, including bacterial, viral, or fungal infections (common cold and onychomycosis excluded). Any anti-infective treatment must be completed at least 2 weeks before dosing. History of infection or HIV antibody positive at screening. Positive treponemal antibody for syphilis at screening. Active pulmonary tuberculosis, defined as evidence of active TB on chest imaging or other relevant assessments within 3 months before first dosing or during screening. Active hepatitis at screening, defined as: positivity; or HBcAb positivity with HBV DNA ≥ 30 IU/mL; or antibody positivity with detectable HCV RNA.
  • Active bleeding involving the gastrointestinal tract, respiratory tract, central nervous system, or other sites.
  • History of diseases that, in the investigator's judgment, may pose a risk to the participant's safety if enrolled in the study, or may interfere with the assessment of efficacy or safety during the study, including but not limited to: 1. Cardiovascular diseases: history within the past year of acute myocardial infarction or unstable angina, severe arrhythmias (e.g., frequent multifocal ventricular premature beats, ventricular tachycardia, ventricular fibrillation), congestive heart failure, arterial or venous thrombosis, or (NYHA) class III-IV heart failure. 2. History of psychiatric disorders or presence of severe cerebrovascular disease or cognitive sequelae.
  • Treatment with mycophenolate mofetil, tacrolimus, sirolimus, cyclophosphamide, anti-CD52 monoclonal antibody, or other similar therapies within 4 weeks or 5 half-lives of the first dose of the investigational product, whichever is shorter.
  • Planned participation in another clinical trial, or prior exposure to investigational products in another clinical trial within 4 weeks or within 5 half-lives of the first dose of the investigational product, whichever is shorter.
  • Received a within 4 weeks before the first dose of the investigational product, planned administration of a live attenuated vaccine during the study, or received a COVID-19 vaccine within 7 days before dosing.
  • Prior treatment with a JAK inhibitor.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study; female participants of and male participants whose partners are of childbearing potential who do not agree to use highly effective throughout the study period (from signing the ICF until 6 months after the last dose of the investigational product), or those planning to donate oocytes or sperm during the study.
  • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

Phase II:

Inclusion Criteria:

  • According to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition) and the Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (Br J Haematol. 2024; 204: 784-804), the patient is diagnosed with primary acquired AA and meets the diagnostic criteria for SAA.
  • Meets the diagnostic criteria for severe aplastic anemia (Br J Haematol. 2024; 204: 784-804), which require: 1. Bone marrow cellularity less than 25% of normal; if ≥ 25% but \< 50%, residual hematopoietic cells must be \< 30%. 2. Peripheral blood counts must meet at least two of the following three criteria: (ANC) \< 0.5 × 10\^9/L, Absolute reticulocyte count \< 60 × 10\^9/L, count (PLT) \< 20 × 10\^9/L
  • Unsuitable for or unwilling to undergo allogeneic hematopoietic stem cell transplantation.
  • Age ≥ 18 years
  • ECOG performance status ≤2
  • Willing and able to comply with the requirements for this study and written informed consent.

Exclusion Criteria:

  • Presence of any other primary or secondary bone marrow failure syndrome, including but not limited to Fanconi anemia, myelodysplastic syndrome (MDS), clonal cytopenia of undetermined significance, or large granular lymphocytic leukemia.
  • Bone marrow reticulin fibrosis ≥ grade 2
  • Subjects with a paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50% or with evidence of active hemolysis.
  • Presence of clonal cytogenetic abnormalities characteristic of MDS, excluding +8, del(20q), and -Y.
  • Participation in another clinical trial and use of investigational products or medical devices within 30 days prior to the first dose of the investigational product or within 5 half-lives of the investigational product, whichever is longer.
  • Prior use of any of the following before the first dose of the investigational product: rabbit anti-thymocyte globulin (rATG) or porcine anti-lymphocyte globulin (pALG); alemtuzumab; or medium- to high-dose cyclophosphamide (≥30-45 mg/kg/day).
  • Prior use of standard-dose cyclosporine or standard-dose TPO-RA for more than 1 month before the first dose of the investigational product.
  • Bleeding and/or infection that remain uncontrolled despite receiving standard therapy prior to the first dose of the investigational product.
  • Active CMV or EBV infection.
  • History of, or concurrent presence of: Positive human immunodeficiency virus (HIV) antibody test; Positive hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) with HBV DNA above the assay upper limit of quantification.
  • Uncontrolled conditions prior to the first dose of the investigational product, including: 1. Hypertension: blood pressure remains uncontrolled despite lifestyle modification and treatment with two or more appropriately dosed, tolerable antihypertensive drugs (including diuretics) for more than 1 month, or requiring four or more antihypertensive drugs for effective control. 2. Severe arrhythmias, such as complete left bundle branch block, atrial fibrillation, or torsades de pointes. 3. Unstable angina. 4. Pulmonary hypertension, defined as estimated pulmonary artery systolic pressure (PASP) ≥ 60 mmHg by echocardiography. 5. Active bleeding involving the gastrointestinal tract, respiratory tract, central nervous system, or other sites.
  • Any arterial or venous thrombosis within 1 year prior to the first dose (excluding fully resolved deep or superficial venous thromboembolism), such as myocardial infarction or pulmonary embolism.
  • History of other within 5 years prior to the first dose (excluding cured early-stage tumors such as basal cell or squamous cell skin cancer, early-stage papillary thyroid cancer, superficial bladder cancer, cervical or breast carcinoma in situ, or localized prostate cancer with Gleason score \<6).
  • Pregnant or breastfeeding.
  • Presence of to rATG, pALG, or cyclosporine.
  • Prior treatment with a JAK inhibitor.
  • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    JAK1 inhibitor

    Phase Ib: Dose escalation follows the "3+3" principle. Participants will receive golidocitinib 150 mg every other day (qod) or 150 mg once daily (qd) for 12 consecutive weeks. Based on the clinical trial data obtained (e.g., safety, maximum tolerated dose), the recommended Phase II dose (RP2D) will be determined following discussion by the SRC. Phase II: Participants will receive golidocitinib at the RP2D in combination with intensive immunosuppressive therapy for 12 consecutive weeks. intensive immunosuppressive therapy regimen: * Porcine anti-lymphocyte globulin (pALG): 25 mg/kg/day or Rabbit anti-thymocyte globulin (rATG): 3.0 mg/kg/day × 5 days, * Cyclosporine: 3-5 mg/kg/day, * Eltrombopag: 15 mg/day.

    Drug: Golidocitinib Capsules

Interventions

  • DrugGolidocitinibStudies of GolidocitinibGolidocitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In phase Ib, the low-dose cohort will receive golidocitinib 150 mg orally every other day (qod), and the high-dose cohort will receive golidocitinib 150 mg orally once daily (qd).

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    This primary outcome measure applies to Phase Ib, and adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Within 12 weeks

  2. Percentage of patients with complete hematological response

    This primary outcome measure applies to Phase II, and a complete hematological response (CR) is defined as meeting all of the following criteria: 1) HGB ≥ 100 g/L; 2) PLT ≥ 100 × 10\^9/L; 3) ANC ≥ 1.0 × 10\^9/L.

    Time frame: Within 3 months post treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 1, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297550
Responsible party
Jun Shi (Director of the Red Blood Cell Diseases Center & Director of the Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Dec 22, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Lele Zhang, PhD
Contact
zhanglele@ihcams.ac.cn
‭15811139278‬

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion